On March 2, 2026 Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, reported that management will participate and be available for one-on-one meetings at the following investor conferences:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Leerink Global Healthcare Conference
Monday, March 9, 2026 – One-on-one meetings
Wednesday, March 11, 2026 – Fireside chat at 9:20 a.m. ET
Citizens Life Sciences Conference
Tuesday, March 10, 2026 – One-on-one meetings
Fireside chat at 2:15 p.m. ET
Jefferies Biotech on the Beach Summit
Wednesday, March 11, 2026 – One-on-one meetings only
Barclays 28th Annual Global Healthcare Conference
Thursday, March 12, 2026 – One-on-one meetings
Fireside chat at 10:30 a.m. ET
Webcasts of the fireside chats at the Leerink, Citizens and Barclays conferences will be available via the Events section of the Altimmune website.
Registered investors may request meetings on the dates noted above via their sales contacts at the respective banks.
(Press release, Altimmune, MAR 2, 2026, View Source [SID1234663190])